WALD Earnings Prediction
The chart below shows how WALD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, WALD sees a +0.81% change in stock price 10 days leading up to the earnings, and a +21.38% change 10 days following the report. On the earnings day itself, the stock moves by -0.15%. This data can give you a slight idea of what to expect for the next quarter's release.
WALD Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
WALD Earnings Analysis
Waldencast plc Class A Ordinary Share Corporation (WALD.O) Earnings Conference Call
Positive
Accelerated Revenue Growth: Comparable net revenue growth of 34.6% accelerated from 21% in Q1 and 25.7% in Q2, reflecting increased consumer demand for our Obagi Medical and Milk Makeup brands.
Net Revenue Surge: Net revenue reached $70.2 million, representing a strong 34.6% increase in comparable growth.
EBITDA Growth and Expansion: Adjusted EBITDA rose 134% to 16.3% of net revenue, expanding 720 basis points from the prior year, showcasing robust growth and operational leverage.
Net Revenue Increase: For the first nine months of 2024, net revenue reached $201.8 million, a solid 26.9% increase in comparable growth.
Adjusted Gross Profit Surge: Adjusted gross profit came in at $150.9 million, up 37%, with an adjusted gross profit margin of 74.8%, a 720 basis point improvement compared to the first nine months of 2023.
Negative
Gross Profit Margin Decline: Adjusted gross profit margin of 66.6% declined 340 basis points from last year, driven by a shift in mix with increased lower-margin holiday kits shipping in Q3 this year versus last year.
Adjusted Gross Profit Surge: Adjusted gross profit came in at $150.9 million, up 37%, with an adjusted gross profit margin of 74.8%, a 720 basis point improvement compared to the first nine months of 2023.
EBITDA Growth and Sales Surge: Adjusted EBITDA grew by 54.9% to $29.1 million, driven by strong sales growth and improved gross margin, which more than offset our increases in marketing expenses.
Net Debt and Shares Outstanding: We ended the first nine months of 2024 in a solid financial position with net debt totaling $154 million, and as of November 15, 2024, shares outstanding were 122.9 million.
Supply Chain Improvement: We have seen a bit of our own issues in terms of our ability to supply with out of stocks and so on and so forth that is starting to normalize have improved substantially this quarter.
WALD FAQs
How does WALD typically perform around its earnings report dates?
Is Waldencast plc. (WALD) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
WALD Earning Call Sentiment
Waldencast plc. (WALD) Q3 2024 Earnings Call Transcript
WALD.O
-0.94%Positive
The earnings call presents strong financial performance with significant revenue and EBITDA growth for both Milk Makeup and Obagi Medical. Despite a slight decline in Milk Makeup's gross margin, the overall financial health is robust, supported by improved operational efficiencies. The Q&A highlights optimism in innovation and minimal tariff impact, with plans to manage gross margins effectively. While management avoided specific details on brand awareness, the overall sentiment remains positive due to strong growth metrics and strategic initiatives, suggesting a likely positive stock price movement in the short term.
